SILENCE THERAP. SP.ADR/1 (XRP2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) has a cash flow conversion efficiency ratio of -0.277x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.29 Million ≈ $-20.21 Million USD) by net assets (€62.30 Million ≈ $72.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SILENCE THERAP. SP.ADR/1 market cap and net worth for the company's overall valuation and market capitalisation.
SILENCE THERAP. SP.ADR/1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how SILENCE THERAP. SP.ADR/1's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SILENCE THERAP. SP.ADR/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SILENCE THERAP. SP.ADR/1 ranked by their cash flow conversion efficiency. See SILENCE THERAP. SP.ADR/1 (XRP2) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Roman DBDR Acquisition Corp. II Ordinary shares
NASDAQ:DRDB
|
-0.001x |
|
WildBrain Ltd
TO:WILD
|
0.095x |
|
888 Holdings plc
F:C8V
|
-0.007x |
|
Foghorn Therapeutics Inc
NASDAQ:FHTX
|
0.233x |
|
RoadMain T Co Ltd
SHG:603860
|
-0.023x |
|
Lanzhou Huanghe Enterprise Co Ltd
SHE:000929
|
-0.200x |
|
Shanghai Baolijia Chemical Co. Ltd.
SHE:301037
|
N/A |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
Annual Cash Flow Conversion Efficiency for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. View XRP2 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €62.30 Million ≈ $72.84 Million |
€-62.27 Million ≈ $-72.80 Million |
-0.999x | -98.04% |
| 2024-12-31 | €134.02 Million ≈ $156.69 Million |
€-67.64 Million ≈ $-79.08 Million |
-0.505x | +77.56% |
| 2023-12-31 | €21.99 Million ≈ $25.71 Million |
€-49.46 Million ≈ $-57.83 Million |
-2.249x | -5.31% |
| 2022-12-31 | €26.71 Million ≈ $31.23 Million |
€-57.04 Million ≈ $-66.69 Million |
-2.136x | -367.53% |
| 2021-12-31 | €11.51 Million ≈ $13.45 Million |
€9.19 Million ≈ $10.74 Million |
0.798x | -- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more